Want to join the conversation?
In 1Q16, $ABBV's global IMBRUVICA net revenues were $381MM. US sales were $325MM and international profit sharing was $56MM. Global VIEKIRA sales were $414MM in 1Q16. Global sales of Duodopa grew 36.7% operationally and the company saw continued double digit growth internationally with a modest level of US sales.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?